Briefing.com uses cookies to store information on your computer that is essential to making the site work and to customizing the user experience. By using the site, you consent to the placement of these cookies. Read our cookie policy to learn more and how to withdraw your consent.     
You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • Google+
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >Biogen Spikes After Positive...
Story Stocks® Archive
Last Update: 06-Jul-18 09:19 ET
Biogen Spikes After Positive Clinical Study Results (BIIB)

Biogen (BIIB 343.20, +44.39) has spiked 14.9% in premarket after the company's Phase II study of an anti-amyloid beta protofibril antibody showed positive results in patients with early Alzheimer's disease. Today's pre-market gain has lifted Biogen to levels not seen since early February.

Biogen's Study 201 is being conducted in collaboration with Japan's Eisai. Shares of Eisai spiked 19.5% in Tokyo overnight.

Last evening, the two companies announced that Study 201, a study of 856 patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia, achieved statistical significance on key endpoints at 18 months. The study showed slowing progression in Alzheimer's Disease Composite Score and a reduction of amyloid accumulated in the brain, measured with a PET scan.

The drug candidate showed acceptable tolerability profile through 18 months of administration with infusion-related reactions representing the most common side effect. These reactions were mostly mild to moderate in severity. The two companies will present detailed results of the study at future academic conferences.

Eisai's Chief Clinical Officer and Chief Medical Officer of the company's Neurology Business Group, Lynn Kramer, M.D., commented on the results, saying "This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis."

Biogen (BIIB 343.20, +44.39) has spiked 14.9% in premarket after the company's Phase II study of an anti-amyloid beta protofibril antibody showed
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Request a Demo
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Cookie Policy
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup